Expanding what’s possible for people living with TGCT
At SynOx Therapeutics, we are focused on improving the lives of people living with rare diseases, combining deep industry expertise and innovative science to develop targeted therapy for tenosynovial giant cell tumor (TGCT) and other inflammatory and autoimmune disorders.
Emactuzumab: A targeted approach to TGCT
Emactuzumab is a monoclonal antibody being developed for the treatment of tenosynovial giant cell tumor (TGCT). It is designed to target CSF-1R, a receptor that plays an important role in the biology of TGCT. 1
In TGCT, abnormal signalling through the CSF-1 and CSF-1R pathway leads to the accumulation of macrophages and other cells within the affected joint. 1 By blocking CSF-1R, emactuzumab is designed to address this underlying disease biology. 2
Patient-focused innovation
SynOx was founded with a clear purpose: to improve the lives of people living with TGCT. We believe that although TGCT is a rare condition, the people affected by it deserve the same commitment to innovation, research, and support as anyone living with a more common disease.
Our values
We place patients at the heart of every decision
We innovate boldly and adapt as we learn
We share openly, support each other and succeed together
We place patients at the heart of every decision
Meet our leadership team
Our team is united by a shared commitment to improving life for people living with TGCT. Our scientists, clinicians, patient advocates and business leaders bring deep experience across science, medicine, rare disease and biotechnology, working together to advance meaningful new treatment options. Above all, we put patients first.
Ray Barlow
Chief Executive Officer
I am pleased to be part of such a dedicated team, with extensive combined experience of developing biological products through to approval and commercialisation. We are focused on the continued development of emactuzumab as a differentiated, next-generation treatment for patients with TGCT and other macrophage-driven pathologies around the globe. This is a critical and exciting stage of the company’s journey and we all look forward to pursuing our mission.
Events
CTOS Annual Meeting
18-21 November in Seoul
Investors
SynOx is backed by a world-class group of life science investors who share our commitment to improving outcomes for people living with rare diseases.
(1) Stacchiotti S, et al. Best clinical management of tenosynovial giant cell tumor (TGCT): A consensus paper from the community of experts. Cancer Treat Rev. 2023;112:102491. doi:10.1016/j.ctrv.2022.102491[SC2.1]
(2) Gelderblom, H. et al. (2026). TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors. Future Oncology, 22(18), 2109–2119. https://doi.org/10.1080/14796694.2026.2702768